On October 2, 2024, in the context of their successful restructuring proceedings under the Companies’ Creditors Arrangement Act, IntelGenx Corp. and IntelGenx Technologies Corp. (together, IntelGenx) entered into a transaction with Atai Life Sciences AG (Atai) whereby Atai acquired all of the issued and outstanding shares IntelGenx through a “credit bid” transaction, structured as a “reverse vesting order”. The monitor provided significant support in the process leading to the closing of the transaction and the exit of IntelGenx from the Companies Creditors’ Arrangement Act process.
Osler, Hoskin & Harcourt LLP represented Ernst & Young Inc. (EY) with a team consisting of Sandra Abitan, Ilia Kravtsov and Jack M. Little (Insolvency & Restructuring).
Key Contact
Montreal Managing Partner, Montréal
Team
Associate, Insolvency and Restructuring | Disputes, Montréal
Associate, Insolvency and Restructuring, Montréal
